GlassScriptPhysician profile
Daniel A London
NPI 1053706192
$12,967.84
in general payments reported to CMS, 2019-2025
13 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Surgery of The Hand (Surgery) provider received nationally (typical 2025 total: $285).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,407 · 2022: $3,857 · 2023: $406 · 2024: $123 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603 · Consulting Fee: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.14 |
| Consulting Fee | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $3,491.52 | 2021 | |
| Elite Orthopedics, LLC | $2,441.72 | 2021-2022 | |
| Skeletal Dynamics INC | $2,297.95 | 2021 | |
| Axogen | $1,609.16 | 2021-2025 | Avance Nerve Graft |
| Trimed, INC. | $1,284.05 | 2021 | |
| Legacy Ortho LLC | $1,200.00 | 2021 | |
| Checkpoint Surgical, INC | $311.74 | 2023-2025 | Checkpoint Stimulators |
| Acumed LLC | $105.10 | 2024 | Inframe Implant |
| Integra Lifesciences Corporation | $93.46 | 2022-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Depuy Synthes Products, INC. | $54.90 | 2023 | Fibergraft Aeridyan Matrix, Fibergraft Bg Morsels |
| Smith+Nephew, INC. | $38.85 | 2021 | |
| Vericel Corporation | $22.43 | 2025 | Nexobrid |
| Endo Pharmaceuticals INC. | $16.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel London listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.